European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant) for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.
Pfizer (NYSE:PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) entered into an agreement for the commercialization of VYDURA, Pfizer has commercialization rights to rimegepant in markets outside the U.S., while Biohaven continues to lead research and development globally and retains the U.S. market.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Nick Lagunowich, Global President, Pfizer Internal Medicine, commented, ”There is a significant unmet need for people in the European Union living with the pain and disability caused by frequent migraines”.
Earlier in February, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended rimegepant for the approval.
Pfizer is trading at $49.16 in the pre-market session.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.